Enlivex Therapeutics Ltd Stock News

ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m.

Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetra™ for injection into the tempo...

Nes-Ziona, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra™ trial in patients with moderate to severe knee osteoarthritis.

NESS ZIONA, ISRAEL / ACCESSWIRE / November 26, 2024 / Enlivex Therapeutics Ltd. (Nasdaq:ENLV)(the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on December 3, 2024, at 11:00 a.m.

Nes-Ziona, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period for the first patient in its Phase I clinical trial evaluating the safety, tolerability and potential therapeutic effect of Allocetra™ following in...

Nes-Ziona, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Japanese Patent Office issued a notice of allowance for patent application number 2022-512861 titled “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS”. Once issued, the resulting patent...

Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed an interim data review at the conclusion of the Phase I safety run-in stage of the Company's ongoing Phase I/II clinical trial of ...

ORLANDO, FL / ACCESSWIRE / August 30, 2024 / RedChip Companies will air interviews with GreenPower Motor Company Inc. (Nasdaq:GP) and Enlivex Therapeutics Ltd. (Nasdaq:ENLV) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 31, at 7 p.m.